Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report
Abstract Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/kexin type 9 levels directly correla...
Main Authors: | Tanawan Kongmalai, Nalinee Chuanchaiyakul, Yuttana Srinoulprasert, Nuntakorn Thongtang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13256-023-03804-5 |
Similar Items
-
Does pathological type of primary nephrotic syndrome affect serum concentrations of proprotein convertase subtilisin/kexin type 9?
by: Howayda El Shinnawy, et al.
Published: (2022-09-01) -
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients
by: Gianluigi Cuomo, et al.
Published: (2022-06-01) -
Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome
by: Huaying Shen, et al.
Published: (2020-01-01) -
Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders
by: Gupta S
Published: (2016-11-01) -
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022-03-01)